- Home
- SNDX vs TRIP Comparison
SNDX vs TRIP Comparison
Compare SNDX & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDX | TRIP |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SNDX | TRIP |
|---|---|---|
| Price | $9.27 | $7.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | ★ $35.45 | $11.57 |
| AVG Volume (30 Days) | 3.7M | ★ 5.7M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.56 | ★ 675.00 |
| EPS | ★ N/A | N/A |
| Revenue | $172,352,000.00 | ★ $1,556,000,000.00 |
| Revenue This Year | $83.56 | N/A |
| Revenue Next Year | $45.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $9.15 | $6.78 |
| 52 Week High | $25.59 | $15.73 |
Technical Indicators
Market Signals| Indicator | SNDX | TRIP |
|---|---|---|
| Relative Strength Index (RSI) | 25.78 | 35.11 |
| Support Level | N/A | N/A |
| Resistance Level | $25.38 | $11.53 |
| Average True Range (ATR) | 1.06 | 0.52 |
| MACD | -0.17 | -0.20 |
| Stochastic Oscillator | 2.78 | 12.12 |
Price Performance
Historical ComparisonAbout SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.